Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06459180
Status:
RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-06-10
Brief Title:
A Study to Compare Sacituzumab Tirumotecan MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer MK-2870-020TroFuse-020Gog-3101ENGOT-cx20
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-05
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-10-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-10-23
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-10
First Submit QC Date:
June 10 2024
Study First Post Date:
2024-06-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-17
Last Update Post Date:
2024-06-14
Last Update Post Date Type:
ACTUAL